Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kava for Nicotine and NNK Metabolism in Smoking Head and Neck Cancer Survivors
NCT03606655Phase 1Withdrawn
- Sponsor
- University of Florida
- Start
- Jan 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of kava in Tobacco Use Disorder (TUD), sponsored by University of Florida. Primary endpoints: Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol at 2 weeks, Ratio of total NNAL-glucuronide to NNAL at 2 weeks and 1 more. Planned start Jan 2020; status: withdrawn.
02
Drugs
kava
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03606655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606655.